Phaseline

Targets › DNMT3B

DNMT3B (DNA): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

DNA (cytosine-5)-methyltransferase that mediates genome-wide de novo methylation and which is essential for the establishment of DNA methylation patterns during development. Modifies DNA at CpG sites with selectivity for residues flanking the target CpG site at positions -1 and +1, and strong preference for a guanine (G) immediately following the CpG sites. (UniProt, Q9UBC3)

Open in Phaseline: the race on DNMT3B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Guadecitabine
DNA methyltransferase (DNMT) inhibitor
DNMT1, DNMT3A, DNMT3BPhase 2Locally Advanced Unresectable Primary Central ChondrosarcomaJan 2027
University of Southern CaliforniaGuadecitabine
DNMT inhibitor
DNMT1, DNMT3A, DNMT3BPhase 1Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic LeukemiaDec 2026

Conditions

Extrahepatic Bile Duct Adenocarcinoma, Biliary Type (1) Chronic Myelomonocytic Leukemia (1) Locally Advanced Unresectable Primary Central Chondrosarcoma (1)

Modalities

mixed (1), small molecule (1)

Companies

University of Southern California (1) National Cancer Institute (NCI) (1)

Related targets

DNMT1 (2) DNMT3A (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.